Welcome to our dedicated page for ZIOP news (Ticker: ZIOP), a resource for investors and traders seeking the latest updates and insights on ZIOP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZIOP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZIOP's position in the market.
Ziopharm Oncology (Nasdaq: ZIOP) announced a conference call and webcast scheduled for August 6, 2020, at 4:30 pm EDT. The call will provide a corporate update and discuss financial results for Q2 2020, ending June 30, 2020. Investors can access the call by dialing designated numbers in the U.S. and internationally, with a passcode provided. The live webcast will be available on the company’s website, allowing for a subsequent archived recording for two weeks. Ziopharm specializes in immuno-oncology with its non-viral Sleeping Beauty platform for T-cell therapies.
Ziopharm Oncology has appointed James Huang to its Board of Directors, enhancing its leadership with his extensive experience in biotech. With over 20 years in the industry, Huang has co-founded several successful firms and serves as Managing Partner at Kleiner Perkins Caufield & Byers China. He aims to leverage Ziopharm's non-viral Sleeping Beauty platform for innovative cancer treatments. The company is advancing its joint venture, Eden BioCell, which focuses on CAR-T therapies, with $35 million committed by TriArm Therapeutics for clinical development in Greater China.
Ziopharm Oncology announced the launch of a phase 1 clinical trial for CD19-specific CAR-T therapy using its Rapid Personalized Manufacturing (RPM) technology, targeting patients with relapsed CD19+ leukemias and lymphomas. The trial, enrolling up to 24 patients at The University of Texas MD Anderson Cancer Center, aims to assess the safety and maximum tolerated dose of genetically modified T cells. The innovative RPM approach allows for overnight T cell reprogramming, showing promise in addressing limited treatment options for these patients.
Ziopharm Oncology (Nasdaq: ZIOP) announced the appointment of Dr. Carl June as Chairman of its new Scientific Advisory Board. Dr. June is a prominent figure in oncology and immunotherapy, recognized for his pioneering work in gene therapy and T-cell therapies. His leadership is expected to help guide Ziopharm's innovative technologies aimed at treating solid tumors. The company emphasized its commitment to developing effective therapies using its owned Sleeping Beauty platform, focusing on scalable and efficient cancer treatments.
Ziopharm Oncology (Nasdaq: ZIOP) announced that CEO Laurence Cooper will participate in a panel titled Cell Therapy: Promise of the Next Generation at the Raymond James Human Healthcare Innovation Conference on June 17, 2020, at 12:00 p.m. ET. The panel will be hosted by equity research analysts Dane Leone and David Novak. Investors can access the live presentation or the archived recording via the Investors section of the Ziopharm website. Ziopharm is focused on developing innovative cell and gene therapies for solid tumors.
BOSTON, May 27, 2020 – Ziopharm Oncology (Nasdaq: ZIOP) announced that CEO Laurence Cooper will participate in a virtual fireside chat at the Jefferies 2020 Healthcare Conference on June 3, 2020, at 3:00 p.m. ET. Investors can access the live webcast and the archived recording via the "Investors" section of the Ziopharm website. Ziopharm focuses on developing innovative cell and gene therapies aimed at treating solid tumors through its unique non-viral gene transfer platform and strategic partnerships with major cancer research institutions.
BOSTON, May 08, 2020 – Ziopharm Oncology (Nasdaq: ZIOP) announced that CEO Laurence Cooper will participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 5:00 p.m. ET. An audio webcast will be available live, accessible through the Investors section of the Ziopharm website, with a recording available until August 12, 2020. The company focuses on developing non-viral, cytokine-driven cell and gene therapies to treat solid tumors, utilizing innovative platforms such as Sleeping Beauty.